Wintech Nano
688757
CHANGFU CO.,LTD
871396
DIER CHEMICAL
831304
4
CHENGUANG MEDICAL
430300
5
TLC
873576
CN Stock MarketDetailed Quotes
600269 Jiangxi Ganyue Expressway
- 5.22
- -0.03-0.57%
Not Open Mar 25 15:00 CST
12.19BMarket Cap9.53P/E (TTM)
5.23High5.07Low420.39KlotVolume5.16Open5.25Pre Close216.06MTurnover1.80%Turnover Ratio9.53P/E (Static)2.34BShares5.7652wk High0.65P/B12.19BFloat Cap4.0652wk Low5.78Limit Up2.34BShs Float8.65Historical High4.73Limit Down3.05%Amplitude-0.91Historical Low0.16Dividend TTM5.14Avg Price192.69KlotAsk3.07%Div YieldTTM100Lot Size216.30KlotBid
Jiangxi Ganyue Expressway Key Stats
All
YOY
| (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -20.12%5.99B | -12.69%4.56B | -7.22%3.22B | 0.19%1.56B | 10.86%7.49B | 18.38%5.22B | 12.61%3.47B | -17.30%1.56B | 5.11%6.76B | 6.44%4.41B |
| Operating revenue | -20.12%5.99B | -12.69%4.56B | -7.22%3.22B | 0.19%1.56B | 10.86%7.49B | 18.38%5.22B | 12.61%3.47B | -17.30%1.56B | 5.11%6.76B | 6.44%4.41B |
| Other operating revenue | 62.55%60.85M | ---- | 14.71%17.81M | ---- | 24.78%37.43M | ---- | -2.03%15.53M | ---- | -20.12%30M | ---- |
| Total operating cost | -26.14%4.42B | -17.14%3.23B | -11.93%2.27B | -5.23%1.01B | 8.31%5.98B | 21.73%3.89B | 14.44%2.58B | -20.99%1.06B | 12.35%5.52B | 7.52%3.2B |
| Operating cost | -28.86%3.63B | -19.31%2.66B | -13.33%1.89B | -4.04%822.85M | 11.23%5.11B | 27.40%3.3B | 18.74%2.18B | -24.67%857.44M | 16.99%4.59B | 12.64%2.59B |
| Operating tax surcharges | -21.71%34.32M | -15.14%25.7M | 7.27%15.93M | -9.39%7.95M | 30.78%43.83M | 39.68%30.29M | 1.69%14.85M | 11.55%8.77M | 9.04%33.52M | -12.16%21.68M |
| Operating expense | 2.32%80.43M | 1.76%60.64M | 4.28%42.19M | 22.64%17.39M | 2.82%78.6M | 10.95%59.59M | 7.15%40.46M | -21.39%14.18M | -26.20%76.45M | -9.48%53.71M |
| Administration expense | -3.01%287.34M | 7.91%191.3M | 2.46%122.67M | -6.74%59.97M | 6.81%296.24M | 15.33%177.28M | 12.62%119.73M | 21.63%64.3M | 1.57%277.35M | -8.79%153.71M |
| Financial expense | -20.75%312.26M | -12.25%262.48M | -10.09%185.37M | -15.71%94.28M | -16.36%394.01M | -15.57%299.11M | -13.99%206.17M | -8.37%111.84M | -9.99%471.09M | -11.34%354.27M |
| -Interest expense (Financial expense) | -17.38%339.44M | -11.20%285.95M | -8.85%197.28M | -13.19%102.14M | -18.45%410.84M | -16.13%322.03M | -15.31%216.44M | -8.57%117.66M | -8.58%503.78M | -8.70%383.94M |
| -Interest Income (Financial expense) | -14.99%-37.93M | 35.49%-17.66M | 3.51%-16.56M | -28.97%-9.35M | 35.74%-32.99M | 39.62%-27.38M | 39.77%-17.16M | 33.95%-7.25M | -13.42%-51.34M | -34.53%-45.35M |
| Research and development | 14.02%71.15M | -14.72%25.04M | -12.01%14.47M | -20.53%5.87M | -14.93%62.4M | 10.68%29.36M | -9.17%16.45M | -1.28%7.39M | 20.93%73.36M | 7.94%26.53M |
| Credit Impairment Loss | -32.55%9.72M | -38.39%5.92M | 44.19%4.56M | 397.22%3.65M | 516.01%14.41M | 119.16%9.61M | 106.42%3.16M | 66.92%-1.23M | -126.27%-3.46M | -458.25%-50.17M |
| Asset Impairment Loss | 119.33%13.05M | 460.95%10.79M | 306.84%8.69M | 114.25%6.18M | 29.47%-67.51M | -130.97%-2.99M | -155.39%-4.2M | 3,649.42%2.88M | -254.42%-95.72M | 147.37%9.65M |
| Other net revenue | 58.92%484.83M | 31.55%345.92M | -108.22%-15.59M | -77.88%32.13M | 320.09%305.08M | 261.79%262.97M | 7,566.38%189.66M | 515.69%145.24M | 53.31%-138.62M | 52.76%-162.54M |
| Fair value change income | 58.31%303.29M | 55.88%261.88M | -152.81%-66.35M | -100.99%-1.19M | 234.50%191.58M | 197.40%168M | 1,262.80%125.64M | 413.20%120.74M | 57.95%-142.44M | 56.00%-172.48M |
| Invest income | -41.20%66.62M | -9.43%51.47M | -27.48%28.03M | 26.27%17.97M | 44.32%113.28M | 75.93%56.83M | 115.09%38.65M | 1,116.24%14.24M | 150.28%78.5M | 143.38%32.3M |
| -Including: Investment income associates | -32.83%29.93M | 1,271.97%24.05M | 2.12%12.45M | 426.92%15.51M | 1,264.21%44.56M | -66.67%1.75M | 116.04%12.19M | 247.62%2.94M | -130.82%-3.83M | -29.40%5.26M |
| Asset deal income | 191.87%81.92M | -110.22%-1.3M | -109.57%-1.22M | -79.74%10.91K | 3,870.59%28.07M | 4,102.10%12.74M | 4,102.10%12.74M | -83.82%53.88K | 148.97%706.86K | -3.41%303.15K |
| Other revenue | -59.46%10.23M | -8.57%17.17M | -21.67%10.7M | -35.51%5.51M | 6.00%25.24M | 5.17%18.78M | 17.96%13.67M | 45.00%8.55M | -0.93%23.81M | 8.27%17.85M |
| Operating profit | 13.03%2.05B | 5.50%1.68B | -13.71%934.11M | -8.54%582.85M | 65.56%1.81B | 51.49%1.59B | 30.89%1.08B | 27.48%637.3M | -9.87%1.1B | 27.16%1.05B |
| Add:Non operating Income | 1.88%16.92M | 155.76%19.33M | 165.54%19.15M | 19.75%8.19M | 71.92%16.61M | -44.03%7.56M | -0.75%7.21M | 113.66%6.84M | -94.30%9.66M | -89.80%13.51M |
| Less:Non operating expense | 43.98%213.92M | 158.55%3.68M | 607.26%2.78M | 1,086.62%2.46M | 591.84%148.57M | -4.57%1.42M | -72.17%392.46K | -83.67%207.69K | 50.54%21.47M | -87.20%1.49M |
| Total profit | 10.18%1.85B | 6.07%1.7B | -12.75%950.48M | -8.60%588.58M | 55.19%1.68B | 50.36%1.6B | 30.79%1.09B | 28.31%643.94M | -20.93%1.08B | 12.23%1.06B |
| Less:Income tax cost | 11.89%521.44M | 5.21%463.25M | -14.54%262.29M | -15.77%159.79M | 39.47%466.04M | 42.98%440.33M | 32.84%306.91M | 43.19%189.7M | -10.88%334.15M | 15.25%307.96M |
| Net profit | 9.53%1.33B | 6.40%1.23B | -12.05%688.19M | -5.60%428.79M | 62.20%1.22B | 53.36%1.16B | 30.01%782.45M | 22.97%454.24M | -24.71%749.9M | 11.04%755.53M |
| Net profit from continuing operation | 9.53%1.33B | 6.40%1.23B | -12.05%688.19M | -5.60%428.79M | 62.20%1.22B | 53.36%1.16B | 30.01%782.45M | 22.97%454.24M | -24.71%749.9M | 11.04%755.53M |
| Less:Minority Profit | 35.90%53.02M | 8.61%80.8M | 21.13%61.07M | 22.31%38.03M | -27.65%39.02M | 13.60%74.4M | -2.72%50.42M | -16.51%31.1M | -48.12%53.92M | -15.36%65.49M |
| Net profit of parent company owners | 8.65%1.28B | 6.25%1.15B | -14.33%627.12M | -7.65%390.76M | 69.16%1.18B | 57.14%1.08B | 33.09%732.04M | 27.40%423.14M | -21.99%695.97M | 14.43%690.04M |
| Earning per share | ||||||||||
| Basic earning per share | 10.00%0.55 | 6.52%0.49 | -12.90%0.27 | -5.56%0.17 | 66.67%0.5 | 53.33%0.46 | 29.17%0.31 | 28.57%0.18 | -21.05%0.3 | 15.38%0.3 |
| Diluted earning per share | 10.00%0.55 | 6.52%0.49 | -12.90%0.27 | -5.56%0.17 | 66.67%0.5 | 53.33%0.46 | 29.17%0.31 | 28.57%0.18 | -21.05%0.3 | 15.38%0.3 |
| Other composite income | 152.47%62.28M | 196.80%78.62M | 53.42%-32.4M | 94.63%-2.27M | -227.64%-118.71M | -215.26%-81.21M | -130.53%-69.57M | -114.56%-42.29M | 386.67%93M | 238.59%70.46M |
| Other composite income of parent company owners | 152.47%62.28M | 196.80%78.62M | 53.42%-32.4M | 94.63%-2.27M | -227.64%-118.71M | -215.26%-81.21M | -130.53%-69.57M | -114.56%-42.29M | 386.67%93M | 238.59%70.46M |
| Total composite income | 27.05%1.39B | 21.72%1.31B | -8.01%655.79M | 3.54%426.52M | 30.22%1.1B | 30.45%1.08B | -14.08%712.88M | -37.57%411.95M | -12.53%842.9M | 31.20%825.99M |
| Total composite income of parent company owners | 26.72%1.34B | 22.69%1.23B | -10.23%594.72M | 2.00%388.49M | 34.17%1.06B | 31.90%1B | -14.84%662.47M | -38.83%380.85M | -8.22%788.97M | 37.73%760.5M |
| Total composite income of minority owners | 35.90%53.02M | 8.61%80.8M | 21.13%61.07M | 22.31%38.03M | -27.65%39.02M | 13.60%74.4M | -2.72%50.42M | -16.51%31.1M | -48.12%53.92M | -15.36%65.49M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- |
| Auditor | China Audit Zhonghuan Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- | -- | Daxin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Daxin Certified Public Accountants (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.